Chlamydia Infection Diagnostics Market Segmentation:
Type of Infection (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
The genital chlamydia infection segment in the chlamydia infection diagnostics market is expected to capture 72.5% of the revenue share by 2035. Genital chlamydia infection occurs due to the direct transmission of agents from person-to-person urogenital tract to the eyes and vice versa occurs via contaminated fingers, towels, or other fomites. The rising prevalence of this infection among adults and adolescents is heightening the need for effective diagnostic tools. The advancements in diagnostic technologies such as nucleic acid amplification tests (NAATs), offer higher sensitivity and specificity making chlamydia testing more reliable.
End use (Hospitals, Speciality Clinics, Diagnostic Centers)
The hospital segment is foreseen to account for 52.5% of the global chlamydia infection diagnostics market share through 2035 owing to the large patient base and first preference of patients for medical care. Hospitals provide a multidisciplinary approach to healthcare. Patients often prefer them for chlamydia testing because they can access various services, including counseling, treatment, and follow-up care, all in one place. The presence of skilled healthcare professionals and staff, who can offer more informed and reliable diagnostic and treatment options coupled with the presence of next-gen diagnostic technologies, which enable more accurate and faster testing for chlamydia are contributing to the segmental growth.
Our in-depth analysis of the chlamydia infection diagnostics market includes the following segments:
|
Test Type
|
|
|
Type of Infection |
|
|
End use |
|
